Protocol Ledger

NCT04643470 · Phase II · COMPLETED

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Interventional Phase II clinical trial protocol NCT04643470 sponsored by BeiGene in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-22 Enrollment: 177 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04643470
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)177 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04643470
Protocol FieldVerified Registry Value
NCT IdentifierNCT04643470
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment177 participants (ACTUAL)
Registered Start Date2020-12-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04643470
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Xiamen UniversityXiamen, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital, Sun-Yat Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI